Caring for patients’ mental health in clinical trials
August 6, 2024 | care, clinical trials, mental health, patients
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Mental health awareness week, just like a lot of other awareness weeks and days, is invaluable in bringing attention to important causes. But we also need to remember that those important causes don’t just subside for the other 51 weeks or 364 days of the year.
Which is exactly why we’re talking about mental health in clinical trials now, a few weeks after mental health awareness week. Because this affects patients all year round. For example, almost 1 in 6 cancer patients experience moderate to severe symptoms of anxiety and over 1 in 10 cancer patients experience moderate to severe depression.1 And in one study, it was found that the depression rate increases further to almost 3 in 5 patients when they experience serious adverse events as a byproduct of their treatment.2
Add onto that the demands of a clinical trial, and it can quickly become too much for some patients to deal with. Chronically unwell patients can find constant clinical interferences and interventions exhausting, and patients can easily become physically and mentally exhausted by travelling to and from their appointments.3
Which can quickly become one of the main reasons for people dropping out of clinical trials. A further study also reported that those who report poorer baseline mental health are also less likely to attend assessments and engage with resources, which can also have a lasting impact on trial engagement and recruitment.4 The truth is, there are probably a number of factors playing out, and of course they’re all interlinked.
Mentally exhausted from travelling = decide to not travel = don’t attend assessments.
It’s certainly not cut and dried though. As is often the case.
And whilst we started this article by talking about how awareness of mental health conditions has certainly increased over the last few years, clinical investigation into related conditions remains fraught with challenges, and it is still common practice to exclude patients with known mental health conditions in clinical trials. We know that those with depression tend to be less adherent to treatment, which can have an effect on treatment response. But there is also a need to be fully inclusive.
So, what can we do to support patients’ mental health during trial participation? Prioritising open and regular dialogue with participants, with particular focus on their health beyond just the physical aspects, may help to identify situations where their mental health is being affected. This may require using mental health assessments, including re-assessment at regular touchpoints. Helping patients to understand what is happening during the course of the clinical trial, as well as what will be happening next, is also vital to ensuring they stay informed and feel in control.
And perhaps key is following up with patients, even after trial end. But that is a whole article in and of itself, and so we’ll save that for another day!
References:
- Robberz AS, et al. Support Care Cancer. 2020;28(4):1799–1807.
- Peng Z, et al. Cancer Med. 2023;12(19):20015–20026.
- The Importance Of Looking After A Patient’s Mental Health During Clinical Trials. MD Group. 2020. Link here. Last accessed May 2024
- Jones RA, et al. Int J Behav Nutr Phys Act. 2021;18:146.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.